Nov 5, 2022 Seladelpar Improved the Lipid Profile of Patients With Primary Biliary Cholangitis (PBC): Results From Phase 2 and 3 Clinical Studies
Jun 25, 2022 The selective PPAR-delta agonist seladelpar (MBX-8025) suppresses bile acid synthesis by reducing hepatocyte CYP7A1 through the FGF21 pathway
Jun 21, 2022 Comparative fibroreducing activities of selected nuclear receptor agonists in the carbon tetrachloride mouse model
Jun 21, 2022 Seladelpar Treatment of Patients With Primary Biliary Cholangitis (PBC) For 2 Years Improves the GLOBE PBC Score and Predicts Improved Transplant-Free Survival
May 22, 2022 Treatment With Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and Prior Experience With Obeticholic Acid(OCA) or Fibrates
May 22, 2022 Efficacy, Safety, and Tolerability of Seladelpar in Patients With Compensated Liver Cirrhosis Due to Primary Biliary Cholangitis (PBC) A Pooled Analysis of Phase 2 and Phase 3 Studies
May 22, 2022 Seladelpar Treatment of Patients With Primary Biliary Cholangitis (PBC) For 2 Years Improves the GLOBE PBC Score and Predicts Improved Transplant-Free Survival
Nov 14, 2021 Long-Term Safety and Efficacy of Seladelpar in Patients With Primary Biliary Cholangitis (PBC): 2-Year Results From a Long-Term Study
Nov 12, 2021 Efficacy and Safety of Seladelpar in Patients With Compensated Cirrhosis and Evidence of Portal Hypertension Due to Primary Biliary Cholangitis (PBC)
Nov 12, 2021 Seladelpar reduces established liver and renal fibrosis in the non-obese diabetic inflammation and fibrosis (NIF) mouse model